Showing results (121-130 of 453) with videos related to

Sort By:
Pageof 46
Plos One|October 25, 2011
R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axisHelen J Huang, Laura S Angelo, Jordi Rodon, et al.
Nature Reviews. Clinical Oncology|January 6, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncologyAmber Johnson, Yifei Shen, Xiaofeng Zheng, et al.
Trends in Cancer|July 3, 2021
Targeting the replication stress response through synthetic lethal strategies in cancer medicineNatalie Y L Ngoi, Melissa M Pham, David S P Tan, et al.
Cell|April 17, 2026
Targeting genomic instability in cancerTimothy A Yap, H Charles Manning, Puja Sapra, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 18, 2025
Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutationsTarek Daoud, Jiansong Chen, Peng Wei, et al.
Molecular Cancer Therapeutics|March 25, 2016
Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a ParadigmMichelle L Turski, Smruti J Vidwans, Filip Janku, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract CancerTimothy P DiPeri, Kurt W Evans, Stephen Scott, et al.
Oncotarget|September 1, 2018
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumorsJordi Rodon, Giuseppe Curigliano, Jean-Pierre Delord, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
The Oncologist|August 22, 2014
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinomaJoaquim Bellmunt, Cristina Suarez, Enrique Gallardo, et al.
Pageof 46